Logo image of GTH

GENETRON HOLDINGS LTD-ADR (GTH) Stock Fundamental Analysis

NASDAQ:GTH - Nasdaq - US37186H2094 - ADR - Currency: USD

4.025  +0.01 (+0.12%)

After market: 4.0201 0 (-0.12%)

Fundamental Rating

2

GTH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. GTH has a bad profitability rating. Also its financial health evaluation is rather negative. GTH is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GTH has reported negative net income.
GTH had a negative operating cash flow in the past year.
GTH had negative earnings in each of the past 5 years.
In the past 5 years GTH always reported negative operating cash flow.
GTH Yearly Net Income VS EBIT VS OCF VS FCFGTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 -1B -2B -3B

1.2 Ratios

With a Return On Assets value of -82.89%, GTH is not doing good in the industry: 73.64% of the companies in the same industry are doing better.
With a Return On Equity value of -148.03%, GTH is not doing good in the industry: 65.99% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -82.89%
ROE -148.03%
ROIC N/A
ROA(3y)-90.46%
ROA(5y)-106.52%
ROE(3y)-123.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GTH Yearly ROA, ROE, ROICGTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

1.3 Margins

GTH's Gross Margin of 43.25% is fine compared to the rest of the industry. GTH outperforms 79.08% of its industry peers.
GTH's Gross Margin has improved in the last couple of years.
GTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.2%
GM growth 5Y10.26%
GTH Yearly Profit, Operating, Gross MarginsGTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

GTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GTH has more shares outstanding
GTH has a worse debt/assets ratio than last year.
GTH Yearly Shares OutstandingGTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
GTH Yearly Total Debt VS Total AssetsGTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -8.92, we must say that GTH is in the distress zone and has some risk of bankruptcy.
GTH has a Altman-Z score of -8.92. This is in the lower half of the industry: GTH underperforms 75.68% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that GTH is not too dependend on debt financing.
GTH has a worse Debt to Equity ratio (0.05) than 61.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -8.92
ROIC/WACCN/A
WACC8.31%
GTH Yearly LT Debt VS Equity VS FCFGTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.82 indicates that GTH should not have too much problems paying its short term obligations.
GTH has a Current ratio of 1.82. This is in the lower half of the industry: GTH underperforms 79.59% of its industry peers.
A Quick Ratio of 1.71 indicates that GTH should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.71, GTH is not doing good in the industry: 79.25% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.71
GTH Yearly Current Assets VS Current LiabilitesGTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for GTH have decreased strongly by -61.92% in the last year.
GTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.31%.
The Revenue has been growing by 45.15% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-61.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.82%
Revenue 1Y (TTM)22.31%
Revenue growth 3Y26.24%
Revenue growth 5Y45.15%
Sales Q2Q%342.96%

3.2 Future

The Earnings Per Share is expected to grow by 18.08% on average over the next years. This is quite good.
Based on estimates for the next years, GTH will show a very strong growth in Revenue. The Revenue will grow by 24.46% on average per year.
EPS Next Y20.69%
EPS Next 2Y18.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.16%
Revenue Next 2Y24.46%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GTH Yearly Revenue VS EstimatesGTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
GTH Yearly EPS VS EstimatesGTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GTH. In the last year negative earnings were reported.
Also next year GTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GTH Price Earnings VS Forward Price EarningsGTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTH Per share dataGTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

GTH's earnings are expected to grow with 18.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.08%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENETRON HOLDINGS LTD-ADR

NASDAQ:GTH (3/28/2024, 8:14:34 PM)

After market: 4.0201 0 (-0.12%)

4.025

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap127.29M
Analysts80
Price Target1.39 (-65.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.42
P/FCF N/A
P/OCF N/A
P/B 1.69
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-3.54
EYN/A
EPS(NY)-0.15
Fwd EYN/A
FCF(TTM)-2.37
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS2.84
BVpS2.39
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.89%
ROE -148.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.25%
FCFM N/A
ROA(3y)-90.46%
ROA(5y)-106.52%
ROE(3y)-123.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.2%
GM growth 5Y10.26%
F-Score2
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 106.07%
Cap/Sales 12.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.71
Altman-Z -8.92
F-Score2
WACC8.31%
ROIC/WACCN/A
Cap/Depr(3y)112.06%
Cap/Depr(5y)117.32%
Cap/Sales(3y)13.51%
Cap/Sales(5y)13.9%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.82%
EPS Next Y20.69%
EPS Next 2Y18.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)22.31%
Revenue growth 3Y26.24%
Revenue growth 5Y45.15%
Sales Q2Q%342.96%
Revenue Next Year25.16%
Revenue Next 2Y24.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.08%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.19%
OCF growth 3YN/A
OCF growth 5YN/A